3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
Paclitaxel
74
pembrolizumab
59
Carboplatin
55
Bevacizumab
54
Specimen Handling
47
Magnetic Resonance Spectroscopy
38
Cisplatin
32
olaparib
28
Gemcitabine
25
liposomal doxorubicin
24
Biopsy
20
Taxes
18
Topotecan
17
Nivolumab
17
Doxorubicin
15
Cyclophosphamide
15
Immunoglobulin G
14
Disulfides
14
niraparib
12
fludarabine
12
lenvatinib
11
Surveys and Questionnaires
11
Letrozole
11
atezolizumab
10
Drug Therapy
10
durvalumab
9
Fulvestrant
9
Docetaxel
9
Brachytherapy
9
mirvetuximab soravtansine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glucose
×
Gynecologic
×
90 days
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts